According to the report, Sailong Pharmaceutical Group (002898.SZ) released its semi-annual report for 2024, during the reporting period, the company achieved operating revenue of 0.156 billion yuan, a year-on-year decrease of 0.46%. The net income attributable to shareholders of the listed company was 1.7647 million yuan, a year-on-year decrease of 40.93%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.3731 million yuan. The basic earnings per share was 0.01 yuan.